Argos Therapeutics Announces $6,000,000 Secured Convertible Note Financing
June 16, 2017 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., June 16, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Provides Update on its ADAPT Trial Following Meeting with FDA
May 10, 2017 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., May 10, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial
April 18, 2017 16:05 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., April 18, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
Independent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial of Rocapuldencel-T in Metastatic Renal Cell Carcinoma for Futility Following Its Planned Interim Data Review
February 22, 2017 08:00 ET
|
Argos Therapeutics Inc.
-Company to host conference call today, February 22, 2017 at 8:30am EST- DURHAM, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on...
Argos Therapeutics to Participate in 2017 Genitourinary Cancers Symposium
February 13, 2017 08:30 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Argos Therapeutics to Participate in BIO CEO and Investor Conference
February 06, 2017 08:30 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Argos Therapeutics Completes Lease Agreement for Commercial Manufacturing Space on the Centennial Campus of North Carolina State University
January 19, 2017 16:05 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Argos Therapeutics Enters into Strategic Research Agreement with Personalis, Inc.
December 14, 2016 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Argos Therapeutics Appoints Dr. Ralph Snyderman and Irackly Mtibelishvily to the Company’s Board of Directors
December 13, 2016 08:30 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Argos Therapeutics Reports Highlights from Investor Day in New York City
December 07, 2016 16:30 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...